Copyright
©The Author(s) 2018.
World J Gastroenterol. Jun 21, 2018; 24(23): 2441-2456
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2441
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2441
Table 9 Impact of HBsAg or HBcAb(+) grafts on HBsAg(-) living donor liver transplantation patients
| Ref. | Donor | Incidence of de novo HBV infection (%) | Prevention of de novo HBV infection | Study type |
| Wang[121] (2017) | HBcAb(+) | 4.2 | HBV vaccinations with the aim of achieving anti-HBs > 1000 IU/L pre-transplant and > 100 IU/L post-transplant | RS |
| Xi et al[122] (2013) | HBcAb(+) | 23.9 | No prophylaxis, adefovir, and lamivudine are given to de novo patients | RS |
| Dong et al[123] (2017) | HBcAb(+) | 7.9 | HBIG 100 IU/kg during the operation and lamivudine 3 mg/kg per day after the surgery for at least 1 year until HBV vaccine reaction | RS |
| Loggi et al[124] (2016) | HBsAg(+) | NS | HBIG and lamivudine, adefovir or tenofovir | SR |
| Lei et al[125] (2013) | HBcAb(+) | 15.0 | No specific prophylaxis | RS |
| Lin et al[126] (2007) | HBcAb(+) | 3.3 | Lamivudine monoprophylaxis, HBV vaccinations | RS |
| Hara et al[127] (2016) | HBcAb(+) | NS | Lamivudine first and adefovir dipivoxil were combined with lamivudine 2 yr later | CR |
- Citation: Lan X, Zhang H, Li HY, Chen KF, Liu F, Wei YG, Li B. Feasibility of using marginal liver grafts in living donor liver transplantation. World J Gastroenterol 2018; 24(23): 2441-2456
- URL: https://www.wjgnet.com/1007-9327/full/v24/i23/2441.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i23.2441